Janus Henderson Investors
New York · Late Stage
Also known as JANUS HENDERSON INVESTORS MIDDLE EAST LIMITED · JANUS HENDERSON INVESTORS UK LIMITED · JANUS HENDERSON INVESTORS US LLC · RICHARD BERNSTEIN ADVISORS LLC
What they invest in
from 8 of 8 portfolio companiesBiotech ×6Healthtech ×6Medical Devices ×3AI & Machine Learning ×2Deep Tech ×1Marketplaces ×1PropTech ×1
HQs:United States×4
Investments · 8 tracked
founders shown can be your intro pathBy year:2026 · 32014 · 14 dated
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystNextech Invest+5 more
Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.
BiotechHealthtechMedical DevicesAustin, US
Shanshan Xu(Founder & Chief Executive Officer)inHelmut Jeggle(Co-Founder)Thang Ho(Chief Development Officer)Crystal MacKay(Chief Operating Officer)in
Co-investorsINCE CapitalRA CapitalBiotechnology Value FundREDMILESalvia
Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases.
BiotechHealthtech
Praveen Tipirneni(Chief Executive Officer)Liangsu Wang(Chief Scientific Officer)Zhong Liu(Chief Technology Officer)Aaron Pelta(Chief Business Officer)Colm White(Chief Program Officer)
Co-investorsAtlas VentureLAVvenBio Partners
Apartment List operates an online rental marketplace that uses a quiz-based AI matching system to connect renters with apartments that fit their preferences and lifestyle.
AI & Machine LearningMarketplacesPropTechSan Francisco, US
John Douglas Kobs II(Executive Officer, Director)Charles Christopher Herndon(Executive Officer, Director)John Kobs(Founder)Chris Erickson(Co-founder)
BoardJosh Hannah(Director)Dana Stalder(Director)in
Co-investorsAndre IguodalaAUTHENTIC VENTURESCanaan PartnersGlynn Capital ManagementMatrixTribeca Early Stage Partners+2 more
Calyxo develops medical devices for kidney stone removal, specifically a minimally invasive CVAC (Cavitation-Enabled Ablation and Clearance) system that has been FDA-cleared.
HealthtechMedical DevicesPleasanton, US
Chris Buchko(Executive Officer)Douglas Hughes(Executive Officer, Director)Jee Shin(Executive Officer, Director)Mark Kidd(Executive Officer)Joe Catanese(Executive Officer, Director)
BoardRyan Drant(Director)in
Co-investorsQuesta CapitalAlly Bridge Group
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Aetna Wun Trombley(President and CEO)Amy Bachrodt(Chief Financial Officer)Jeremy S. Caldwell(Executive Officer, Director)Chin Lee(Chief Medical Officer)Steve Staben(Chief Scientific Officer)Sofia Touami(Chief Business Officer)
Co-investorsREDMILEVersant VenturesBAM ElevateFranklin TempletonHBM Healthcare InvestmentsInvus+4 more
Triveni Bio is a clinical-stage biotech company using a genetics-informed approach and antibody engineering to develop therapeutics for immune and inflammatory diseases.
BiotechHealthtech
Vishal Patelin
Co-investorsAtlas VentureMagnetic VenturesOrbiMedAscenta Capital
Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.
BiotechHealthtech
Co-investorsOrbiMedQuan CapitalRA CapitalSanofi VenturesSR One Capital ManagementNovo Holdings+3 more
Exits · 1
IPOs and acquisitions across the tracked portfolioParabilis MedicinesNASDAQ: PBLS
Portfolio news
latest coverage across their companies
Triveni · fiercebiotech.com · Aug 12, 2026
Lycia Therapeutics · intelligence360.news · Jul 22, 2026
Parabilis Medicines · pharmexec.com · Jun 19, 2026
Windward Bio · xtalks.com · May 15, 2026
Calyxo · calyxoinc.com · May 8, 2026
Apartment List · nasdaqprivatemarket.com · Feb 28, 2025
Frequently asked questions
- What stage does Janus Henderson Investors invest at?
- Janus Henderson Investors invests at the Late Stage stage.
- Where is Janus Henderson Investors located?
- Janus Henderson Investors is headquartered in New York, US.
Similar investors
3TS Capital Partners is a private equity and venture capital investor focused on technology and technology-enabled companies, notably in Central and Eastern Europe.
83North is a global venture capital firm that invests in and helps entrepreneurs build large, category-defining companies, backing startups across multiple stages and sectors.
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
Accel is a venture capital firm that partners with exceptional teams, positioning itself as a first partner to founders globally.